miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis

Table 1 Patients’ characteristics (validation cohort)

Characteristics	Control (n = 20)	Inactive UC (n = 19)	Active UC (n = 20)
Gender (male/female)	10/10	6/13	9/11
Age (yr), mean (range)	48 (24-83)	48 (21-69)	38 (16-79)
Age at diagnosis (< 25/> 25 yr)	-	4/15	7/13
Years with disease (< 10/> 10 yr)	-	8/11	15/5
Mayo score, mean (range)	-	0 (0-1)	6 (2-12)
Extension of disease (P/PS/PC/LC/PH)	-		3/3/7/5/2
Smoking/non-smoking	5/15	6/13	3/17
EIM (present/never present)	-	3/16	0/20
Daily medications, n (%)
Systemic mesalazine (1.6-3.2 mg)	-	14 (74)	17 (85)
Topical mesalazine (1000 mg)	-	3 (16)	6 (30)
Systemic glucocorticoids (75 mg)	-	0 (0)	2 (10)
Topical glucocorticoids (100 mg)	-	0 (0)	2 (10)
Azathioprine (100-200 mg)	-	1 (5)	2 (10)
6-mercaptopurine (50-100 mg)	-	0 (0)	1 (5)
Infliximab (5 mg/kg)	-	0 (0)	1 (5)
None	20 (100)	5 (26)	2 (10)

EIM: Extraintestinal manifestations; LC: Left-sided colitis; P: Proctitis; PC: Pancolitis; PH: Proctitis hemorrhagica; PS: Proctosigmoiditis; UC: Ulcerative colitis.